EX-23.1 3 tm2227887d12_ex23-1.htm EXHIBIT 23.1

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated October 14, 2022, with respect to the consolidated financial statements of CARISMA Therapeutics Inc., included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG LLP

Philadelphia, Pennsylvania

January 9, 2023